Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th Read more about Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th
Aimmune Therapeutics Announces Second Quarter 2017 Financial Results Read more about Aimmune Therapeutics Announces Second Quarter 2017 Financial Results
Aimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy Read more about Aimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy
Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy Read more about Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress Read more about Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress
Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017 Read more about Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017
Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy Read more about Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy
Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th Read more about Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th
Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy Read more about Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy
Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy Read more about Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
